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1 Introduction
Tuberculosis (TB) is a lung disease caused by the bacterium Mycobacterium
tuberculosis which kills around 1.5 million people each year and remains a
serious challenge for global public health (WHO 2015). Antibiotic drugs for
treating TB have been available since the mid 20th century, and currently
implemented strategies for TB control rely on the efficacy of these drugs.
Treatment of TB involves combination therapy – in which multiple drugs
are administered together in part to improve killing efficacy. The “first-line”
drugs used in combination to treat tuberculosis are rifampicin, isoniazid,
pyrazinamide, ethambutol and streptomycin.
As with most other pathogens, resistance to antibiotic drugs has rapidly
evolved in M. tuberculosis. Streptomycin was the first of the first-line drugs
to be developed and deployed in 1943, but resistance was observed before the
end of that decade (Mitchison 1951; Gillespie 2002). Of particular concern
is the rise of bacterial strains resistant to multiple drugs, as cases caused by
them are difficult to treat successfully. Multidrug resistance (MDR) is defined
as resistance to both rifampicin and isoniazid. These are the two most effec-
tive drugs against tuberculosis (when the strain is not resistant). Currently,
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3.3% of new TB cases are multi-drug resistant (WHO 2015). The occurrence
of MDR-TB strains that have additional resistance (called extensively drug
resistant, XDR and totally drug resistant, TDR) are particularly problematic
and have the potential to cause large outbreaks that are difficult to control
(Gandhi et al. 2006). A better understanding of how multiple drug resistance
evolves would aid efforts to contain resistance and control tuberculosis.
Genetic studies have established that many independent mutation events
have led to resistance (Ramaswamy and Musser 1998). Although this suggests
that mutation of genes is an important source of resistance, model-based
analysis of molecular data has revealed that among resistant cases, most are
due to the transmission of already resistant bacteria (Luciani et al. 2009). It
is therefore of interest to investigate whether or not this finding also holds
for multi-drug resistant tuberculosis.
The rates at which resistance evolves against different drugs vary. For
instance, isoniazid resistance is known to be acquired faster than rifampicin
resistance (Ford et al. 2013; Gillespie 2002; Nachega and Chaisson 2003). The
rates of mutation to resistance per cell generation are low in absolute value;
for example for isoniazid the rate is around 3× 10−8 and for rifampicin it is
around 2×10−10 (David 1970; Gillespie 2002), although there is a high degree
of variation across different lineages of M. tuberculosis (Ford et al. 2013). One
might therefore expect that double resistance of these drugs (MDR) evolves
at an exceedingly low rate (Nachega and Chaisson 2003). However, MDR
strains often occur at appreciable frequencies (Zhao et al. 2012; Anderson
et al. 2014) and a recent study has presented a theoretical model showing
how double resistance can evolve rapidly within hosts (Colijn et al. 2011). It
would be useful to establish whether such fast direct acquisition of double
resistance can be detected in bacterial isolates from epidemiological studies.
To characterise patterns of TB transmission and drug resistance in a
given geographic region, bacterial isolates from TB patients are often geno-
typed using molecular markers known as variable numbers of tandem re-
peats (VNTRs) which are repeated genetic sequences that exhibit variation
across isolates. The source of this variation is mutation at the VNTR ge-
netic loci which leads to the expansion or contraction of repeat numbers at
those loci (Figure 1). A scheme for discriminating effectively among a set of
isolates involves considering repeat numbers at multiple VNTR sites. This
molecular typing scheme is called multi-locus VNTR analysis (MLVA); in the
context of tuberculosis epidemiology it is often known as mycobacterial inter-
spersed repetitive units-VNTR (MIRU-VNTR) (Mazars et al. 2001; Supply
et al. 2006). Typing techniques such as MLVA have been useful for tracking
particular strains and understanding how drug resistance evolves and dissem-
inates at the epidemiological level (Monteserin et al. 2013; Anderson et al.
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Figure 1: VNTR loci mutate in a stepwise manner so that the number of repeat
units at a locus increases or decreases. In our analysis we assume that when muta-
tion occurs at a locus j in genotype i, the repeat number Vij increases or decreases
by a single copy. We further assume that a single unit (repeat number of 1) is
an absorbing boundary. The hypothetical example shows how mutation at locus
number 13 creates a new VNTR genotype.
2014).
Here, we investigate the rates of drug resistance acquisition in a natural
population using molecular epidemiological data from Bolivia (Monteserin
et al. 2013). First, we study the rate of direct acquisition of double resistance
from the double sensitive state within patients and compare it to the rates
of evolution to single resistance. In particular, we address whether or not
double resistance can evolve directly from a double sensitive state within a
given host. Second, we aim to understand whether the differences in mutation
rates to rifampicin and isoniazid resistance translate to the epidemiological
scale. Third, we estimate the proportion of MDR TB cases that are due to the
transmission of MDR strains compared to acquisition of resistance through
evolution. To address these problems we develop a model of TB transmission
in which we track the evolution of resistance to two drugs and the evolution
of VNTR loci. However, the available data (see Section 2) is incomplete,
in that it is recorded only for a fraction of the population and at a single
point in time. The likelihood function induced by the proposed model is
computationally prohibitive to evaluate and accordingly impractical to work
with directly. We therefore approach statistical inference using approximate
Bayesian computation techniques.
2 Data
The data set we use is taken from a study of tuberculosis in Bolivia (Mon-
teserin et al. 2013). Bolivia has a population of 11 million people and a TB
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incidence of 120 per 100,000 per year. This rate is comparable to the global
incidence of TB (133 per 100,000 per year) and to the rate in Peru, but is 3–6
times the TB incidence in neighbouring countries Brazil, Paraguay, Uruguay,
Argentina and Chile (WHO 2015). In the molecular epidemiological study,
the investigators genotyped 100 isolates collected in 2010, which represented
an estimated 1.1% of the cases in Bolivia at the time of the study (Monteserin
et al. 2013). Each isolate was tested for drug sensitivity to five drugs. Here,
we focus on resistance against the two drugs isoniazid and rifampicin used to
define multidrug resistance. Of the 100 isolates, 14 were found to be MDR,
that is, resistant to both of these drugs, 78 were sensitive to both drugs and
the remaining 8 were resistant to isoniazid but sensitive to rifampicin. No
isolates were resistant to rifampicin while being sensitive to isoniazid.
In addition to these drug resistance profiles, each isolate was genotyped
using 15 VNTR loci. For example, an isolate in the data set, which was re-
sistant to isoniazid but sensitive to rifampicin, had the following 15 repeat
numbers for its 15 VNTR loci: 143533233433527, which together constitute
its genotype. Variation in these genotypes occurs through a process of mu-
tation in which repeat numbers increase or decrease (see Figure 1).
Let g be the number of distinct genotypes present in a sample, and label
the resistance profiles by (0, INH, RIF, MDR), where 0 denotes sensitivity to
both drugs, INH denotes resistance to isoniazid and sensitivity to rifampicin,
RIF denotes resistance to rifampicin and sensitivity to isoniazid, and MDR
denotes resistance to both drugs. The observed data Xobs are then a g × 4
matrix of counts, such that each row gives the distribution of isolates across
the four resistance profiles for a given genotype and each column gives the
distribution of isolates across genotypes for a given resistance profile. The sum
of entries in a particular row is the number of isolates with that genotype,
while the sum of entries in a particular column is the number of isolates with
that resistance profile. The data set also includes a g × 15 matrix of repeat
numbers from the VNTR genotyping.
The Bolivian data set is displayed in full in Table 1, which shows all g = 66
distinct genotypes and classifies all 100 isolates according to genotype and
resistance profile. The Xobs matrix is formed by combining the 0, INH, RIF
and MDR columns.
3 Model
In this Section we introduce a model that incorporates both VNTR-based
genotyping and drug resistance states. The dynamic variables of the model
correspond to numbers of cases of untreated and treated tuberculosis, their
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Genotype 0 INH RIF MDR Genotype 0 INH RIF MDR
253533233433427 4 0 0 0 243413342212437 1 0 0 0
253533233433327 3 0 0 0 233312442212437 1 0 0 0
253533233433527 11 1 0 0 233313441212437 1 0 0 0
253533233433525 3 0 0 0 233413442212248 1 0 0 0
143533233433527 2 1 0 0 233413442212249 1 0 0 0
253333244232232 1 0 0 0 233213442212349 1 0 0 0
25333324423-232 1 0 0 0 231413542212335 1 0 0 0
254333243232342 0 2 0 2 232433242212436 1 0 0 0
263532232423139 3 0 0 0 234413442212436 1 0 0 0
223413442212437 2 0 0 0 434433452212427 1 0 0 0
233413542212347 0 1 0 2 256432342122237 2 1 0 0
244333244232332 0 0 0 1 256433342123236 2 0 0 0
244333244232322 1 0 0 0 247432342122136 1 0 0 0
245333244242332 1 0 0 0 268432252122227 0 1 0 0
254333244232232 0 0 0 1 268632252122227 1 0 0 0
254333244232332 1 0 0 0 221313352122338 0 0 0 1
254333244242332 1 0 0 0 263532233423148 1 0 0 0
253333244242232 1 0 0 0 360332233423138 1 0 0 0
252333243232232 0 0 0 1 263513233523344 1 0 0 0
252333243232332 0 0 0 1 253523233433527 1 0 0 0
251333243242332 1 0 0 0 253533232433527 1 0 0 1
252333243262222 0 0 0 1 253533232433427 1 0 0 0
244233234222322 1 0 0 0 253523133433527 1 0 0 0
233373242232325 1 0 0 0 253533133433527 1 0 0 0
252343242232524 1 0 0 0 353533233433427 0 0 0 1
25233234423251a 1 0 0 0 253533233433837 1 0 0 0
35234234423251a 1 0 0 0 253533233433237 1 0 0 0
233413442212338 0 1 0 0 254533233433537 0 0 0 1
233413442212335 1 0 0 0 253533233433536 1 0 0 0
233413442212337 1 0 0 0 252533233433428 1 0 0 0
21341344221233a 1 0 0 0 253534233433325 1 0 0 0
213413442212327 0 0 0 1 243533232433737 1 0 0 0
233413442212437 3 0 0 0 242433433433436 1 0 0 0
Table 1: Molecular data set compiled from Monteserin et al. (2013). All isolates
were classified according to their genotype and resistance profile. The symbol “a”
represents 10 repeat units and “-” represents missing data. The entries in the four
columns sum to the total number of isolates, 100.
resistance states and VNTR genotypes associated with these infections in
the population. We will now briefly describe processes involved in the model,
and provide further details in the following Subsections.
An untreated case of TB can become detected and treated, and treatment
involves a combination of drugs including the two in question. Drug sensitive
strains can acquire resistance under treatment with some probability and
thereby change their resistance state. Treated and untreated cases can infect
susceptible individuals and convert them to untreated cases. We disregard
latent infections for simplicity (although latency is an important feature of
the natural history of tuberculosis), and focus on active infections which are
the larger source of new infections. Treated and untreated individuals can
also recover or die. Treated individuals enjoy an additional probability of
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recovery that depends on the efficacy of the drugs, which in turn depends
on the sensitivity or resistance of the infecting strain. Treated and untreated
cases are also associated with a VNTR genotype, and this genotype evolves
over time according to a stepwise mutation process for each locus. Figure 2
shows the broad structure of the model with respect to treatment and resis-
tance states, while suppressing details of transmission, recovery, death and
mutation of the VNTR loci.
At the end of the period of evolution, a simple random sample of 100
isolates is taken without replacement from the population, which matches
the sample size of the Bolivian dataset. This provides a full description of
the generative process for the observable data.
Let G be the number of distinct genotypes in the population (the num-
ber of distinct genotypes in the sample is g) and L be the number of VNTR
loci used in the genotyping scheme. For the Bolivian dataset L = 15. In
the model, the variable G is unknown and varies dynamically. We maintain
three matrices which change through time: a G × L matrix, V, which de-
scribes the VNTR genotypes; a G×4 matrix, U, which describes the numbers
of untreated cases of tuberculosis classified according to VNTR genotype and
resistance state; and a G×4 matrix T which describes the numbers of treated
cases of tuberculosis, again classified according to VNTR genotype and re-
sistance state. It will be useful to define a G × 4 matrix, W, whose entries
are the total numbers of both treated and untreated cases: W = U + T.
As it will be helpful to be able to pick out columns of these matrices,
we adopt notation for the standard basis vectors of Rn. Let ei denote the
i-th basis (column) vector, so that ei = (0, · · · , 0, 1, 0 · · · , 0)>, with the 1 in
the i-th position. This allows us, for instance, to write the columns of the
matrix T corresponding to each resistance state as T0 = T e1, TINH = T e2,
TRIF = T e3 and TMDR = T e4, with similar notation for other matrices
(note that the dimension of the ei is left open but inferred from the matrix
multiplication; in this case they are in R4).
Further, writing 1i for the column vector in Ri whose entries are all 1,
then the product T 14 is a G×1 column vector whose entries are the numbers
of individual cases of each VNTR genotype in the treated population, and
the product 1>G T 14 is the sum of all the entries in T (the size of the treated
population). Thus, we can write the size of the susceptible population, S, as
S = N − 1>G W 14,
where 1>G W 14 is the size of the infected population, and where N is the total
population size which remains constant. We treat N as modelling the set of
all individuals who come in contact with infectious cases and so we exclude
6
individuals who either do not encounter infectious cases or are otherwise
protected from infection. This variable therefore may be smaller than the
actual population size.
The components of each vector Tk for k = 0, INH, RIF or MDR, are
integers, representing the number of individual cases for each genotype. In the
schematic diagram of the model in Figure 2, we use Tk = 1
>
G Tk to represent
the total population number of treated individuals with resistance state k,
with similar notation Uk = 1
>
G Uk to represent the untreated populations.
The matrix notation is gathered and shown in Table 2.
The arrows between populations in Figure 2 represent the directional rates
of detection and treatment τ and acquisition of resistance to each drug or set
of drugs, so that ρINH and ρRIF represent rates of acquisition of resistance to
isoniazid and rifampicin respectively and ρMDR the rate of double acquisition.
Symbol Meaning
V G × L matrix describing the VNTR geno-
types.
U, T, W G×4 matrices of untreated, treated and total
cases respectively, with columns correspond-
ing to resistance profiles.
Uk, Tk, Wk G × 1 column vector for resistance profile k
of untreated, treated and total cases respec-
tively.
Uk, Tk, Wk Total population sizes of untreated, treated
and total with resistance profile k.
Ui,k, Ti,k, Wi,k (i, k) entries of the matrices U, T, W: the
number of cases in each category with geno-
type i and resistance profile k.
1i i× 1 column vector whose entries are all 1.
ei Column vector whose entries are 0 except for
1 in position i. Dimension determined by con-
text.
Table 2: Summary of linear algebra notation.
In this model time is discrete, and during each time step the following
events takes place in sequence.
1. Disease transmission giving rise to new cases;
2. Natural recovery, cure or death of cases;
3. Detection of cases which are then treated with drugs;
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4. Conversion among resistant profiles in treated cases due to acquisition
of resistance; and
5. Mutation of the genetic marker (multiple VNTR loci).
The remainder of this Section provides details of how each of these events
are modelled. Readers wishing to focus on the statistical aspects of the ABC
inference can skip these subsections and go directly to Section 4.
We regard the above process as a discrete-time stochastic model rather
than a discrete-time approximation of a continuous-time stochastic process
with rates approximating probabilities, although the latter interpretation
becomes more appropriate as the time step length decreases. Here, rates of
events will be treated as probabilities, which again is appropriate when time
steps are short. The rate parameters are measured in years but we make time
steps 1/12 of a year.
A summary of all model parameters, both fixed and to be estimated, and
their meanings, are provided in Table 3.
3.1 New infections
In our model, new infections occur by mass action. The per capita rate at
which a susceptible individual becomes infected by a case with resistance
profile k is given by βk/N times the number of infected cases in state k. The
transmission parameters βk are scaled by 1/N for convenience since realistic
values of βk/N are typically very small, and this ensures that the βk are on
the natural “per person per unit time” scale.
The acquisition of resistance to antibiotics often comes at a cost to the
fitness of the bacterium, and we implement this fitness cost by assuming
the transmission rate is lower for cases that carry resistance. Specifically,
we assume a cost of “c per drug”, so that if β0 is the transmission rate of
sensitive cases, then cases resistant to one drug transmit at rate βINH =
βRIF = (1 − c)β0 and cases resistant to two drugs at βMDR = (1 − c)2β0.
Here, c = 0.1 is considered known and fixed based on previous analyses of
molecular epidemiological data (Luciani et al. 2009).
We now construct an expression for the average transmission proba-
bility across the infected population. The matrix W records all infected
cases with different resistance states in each column, and the individu-
als corresponding to these columns have different transmission rates β =
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T0
TRIFTINH
TMDR
⇢RIF⇢INH
⇢MDR
⇢RIF ⇢INH
U0
URIFUINH
UMDR
⌧
⌧
⌧
⌧
Background parameters
  death rate
 k recovery rate
 k transmission rate
µ VNTR mutation rate
S susceptible population
Figure 2: Model structure for numbers of untreated (Uk) and treated (Tk) cases
and per capita rates of conversion (within-host substitution) among resistance
classes. Rates are ρINH and ρRIF for acquisition of resistance to isoniazid and
rifampicin respectively, and ρMDR for single step acquisition of resistance to both
drugs. Detection (and treatment) of cases is shown with arrows labelled with τ .
Background parameters are shown in the table to the right, with rates per capita
per unit time, and resistance states k = 0, INH, RIF, MDR. The mutation process
of the VNTR locus is described in Section 3.5.
(β0, βINH, βRIF, βMDR)
>. If we write Dβ for the diagonal matrix whose en-
tries are from β, then the matrix WDβ is the infected population matrix W
whose columns have been scaled by the entries of β (the relevant transmission
rates). The expression
p =
1
N
1TG WDβ 14
then gives the average transmission rate per susceptible individual. Since the
population size N is usually large and the time steps are short, the value for
p will nearly always be small. Accordingly, and to ensure that it does not
exceed 1, we model the probability of transmission per susceptible individual
as p˜ = min{1, p}.
At each time step the number B of new infections is a random variable
distributed as
B ∼ Binomial(S, p˜).
These B new infections are then allocated across VNTR genotypes and resis-
tance profiles according to the proportions represented by the matrix WDβ.
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Symbol Meaning Fixed
value
δ rate of death and natural recovery 0.52
γ0 cure rate for resistance profile 0, when treated 0.5
γINH cure rate for resistance profile INH, when treated 0.25
γRIF cure rate for resistance profile RIF, when treated 0.25
γMDR cure rate for resistance profile MDR, when treated 0.05
N total susceptible population size in absence of disease 104
τ treatment and detection rate 0.5
c cost of resistance 0.1
Symbol Meaning Prior
β0 transmission rate for resistance profile 0 Gamma
∗
µ mutation rate of VNTR per locus per unit time U(0, 1)
ρINH rate of acquisition of resistance to INH U(0, 1)
ρRIF rate of acquisition of resistance to RIF U(0, 1)
ρMDR rate of acquisition of resistance to INH and RIF U(0, 1)
Table 3: Summary of model parameters. The top set of parameters are given fixed
values, whereas the bottom set of parameters are allocated prior distributions
and estimated using ABC. Fixed values and priors are justified in Section 4.2.
Rates are in units of per capita per year, but the time unit is set to 1/12 year in
simulations. ∗Specifically, β0 is assumed to follow a (shifted) Gamma prior defined
as β0− 0.68 ∼ Gamma(shape = 2, rate = 0.73). See Section 4.2 for further details.
That is, a multinomial random sample distributes B according to the existing
infected population and their relative transmission rates, so that the result-
ing allocation is a G×4 matrix ∆β. Finally, as new infections are all assumed
to be initially undetected, they are allocated to the untreated subpopulation,
so that the matrix U is updated to U→ U + ∆β.
3.2 Cure, recovery and death
Infected individuals who are untreated (the population represented by the
counts U) recover or die at rate δ = δr + δd per case per time unit, where
δr > 0 is the rate of recovery and δd > 0 is the rate of death due to any
cause. The rate of cure due to successful treatment may vary according to
resistance profile, so this rate is given by γk for k = 0, INH, RIF, MDR. The
number of cures, recoveries and deaths in a time step is given by
R ∼ Binomial(U, δ)
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for the untreated population, where U = 1>G U 14 is the total number of all
untreated cases, and
Ck ∼ Binomial(Tk, δ + γk),
for the treated population, where Tk is the number of treated individuals with
resistance profile k (as defined at the start of this Section). The R untreated
recovered individuals are distributed across both VNTR genotypes and resis-
tance profiles with a multinomial distribution according to the counts given
in U. These are recorded in the G × 4 update matrix ∆δ (so that the sum
of the entries in ∆δ is R = 1
>
G ∆δ 14). Similarly, the Ck treated recovered in-
dividuals of resistance profile k are distributed across the VNTR genotypes
according to the distribution observed in Tk. These recovered counts for all
resistance profiles are recorded in the G update matrix ∆δ+γ, which is con-
structed from the column vectors of recovered treated counts for profile k
in the order k = 0, INH, RIF and MDR. The matrices U and T are then
updated to U→ U−∆δ and T→ T−∆δ+γ respectively. If the last instance
of any genotype is removed by cure, recovery or death, the matrices U,T,V
are adjusted by removing the rows corresponding to those genotypes, and
the number of genotypes is updated with G→ G− 1.
Similarly to the case of new infections (Section 3.1), we assume that the
recovery rate due to treatment depends only on the number of drugs the
infecting strain is resistant to. Specifically, this implies that γINH = γRIF.
3.3 Detection and treatment
In this model, the detection of cases and the commencement of treatment
are combined as a single process. Detected cases are transferred from the
untreated class to the treated class. We denote this combined detection and
treatment rate, per case, per unit time, as τ > 0. With this rate we draw D
individuals to transfer between untreated and treated populations, where
D ∼ Binomial(U, τ).
These D individuals are then allocated across VNTR genotypes and resis-
tance profiles according to the observed distribution of untreated cases, U.
As before, this results in a G× 4 update matrix ∆τ , which we use to update
U→ U−∆τ and T→ T + ∆τ .
3.4 Acquisition of drug resistance
Individual treated cases are able to convert from one resistance profile to
another through adaptive evolution. That is, under drug treatment, natural
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selection acts to favour increasing levels of resistance. As a result of this
process, individuals may move from the k = 0 resistance profile (sensitive to
both drugs) to one of the other three resistance profiles: INH, RIF, or MDR
(resistance to one or both drugs). Individuals may also move from resistance
to exactly one of the drugs (INH or RIF) to the multiple drug resistance
profile MDR. We respectively denote the rate of acquisition of resistance to
INH or RIF by ρINH and ρRIF, and denote the rate of acquisition of resistance
from individuals in the sensitive population to both drugs simultaneously by
ρMDR. These conversions and rates are illustrated schematically in Figure 2.
To model resistance acquisition, we select individuals to move between
resistance profiles in the treated population i.e. between columns in the ma-
trix T. Acquiring resistance to the drug rifampicin will result in individuals
moving from the column T0 to TRIF, and from TINH to TMDR at a rate ρRIF.
Similarly, acquiring resistance to the drug isoniazid results in individuals
moving from the column T0 to TINH, and from TRIF to TMDR at a rate ρRIF.
Simultaneous acquisition of resistance to both drugs moves individuals from
the column T0 to TMDR at the rate ρMDR. These movements occur between
columns but not across rows (infections do not change VNTR genotypes
through this process).
Mechanistically, we can obtain the number of cases of genotype i tran-
sitioning from resistance profile k to resistance profile k′, denoted Ai,k→k′ ,
as
Ai,0→∗ ∼ Multinomial(Ti,0, ρ0→∗)
Ai,INH→MDR ∼ Binomial(Ti,INH, ρRIF)
Ai,RIF→MDR ∼ Binomial(Ti,RIF, ρINH)
where Ai,0→∗ = (Ai,0→INH, Ai,0→RIF, Ai,0→MDR, Ai,0→0)> is the vector of cases
transitioning from sensitivity, Ti,k is the entry of the matrix T corre-
sponding to the genotype i and resistance profile k (see Table 2), and
ρ0→∗ = (ρINH, ρRIF, ρMDR, 1 −
∑
k ρk)
> is the vector of probabilities of these
events.
If we denote ∆k→k′ as column vectors of counts of movements from resis-
tance profile k to k′ across all G genotypes, we can then construct the overall
G× 4 update matrix
∆ρ = (∆0 | ∆INH | ∆RIF | ∆MDR) .
from the column vectors ∆k, which denote the total population change for
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resistance profile k, where
∆0 = −(∆0→INH + ∆0→RIF + ∆0→MDR)
∆INH = ∆0→INH −∆RIF→MDR
∆RIF = ∆0→RIF∆INH→MDR
∆MDR = ∆0→MDR + ∆RIF→MDR + ∆INH→MDR.
The population of treated cases is then updated to T→ T + ∆ρ.
3.5 Mutation of the marker
The set of L = 15 VNTR loci constitute the genetic marker used to genotype
bacterial isolates (see Section 2). Each genotype is a list of numbers of tandem
repeat units at the L loci. The states of all VNTRs in the infected population
are given by the G × L matrix V with elements Vij describing the repeat
number of locus j in genotype i. Each locus mutates through a stepwise
mutation process at rate µ per locus per case per unit time. When mutation
occurs, the repeat number Vij at a locus j of genotype i changes by +1 or −1,
each with probability 0.5. A repeat number of 1 is treated as an absorbing
boundary (i.e. there is zero probability of the repeat number increasing from 1
to 2) because at state 1 there is no longer a genetic sequence that is tandemly
repeated and no mechanism such as replication slippage acts to expand it
from 1 to 2.
Mutation of the marker has the effect of moving cases between the rows
of the matrix W. We first identify the number of mutation events in the
population,M , whereM ∼ Binomial(S, µ) and S = N−1TG W 14 is the size of
the susceptible population (see Section 3). The M cases are then distributed
across the population of VNTR genotypes and resistance profiles, according
to the entries of the matrices T and U. Each individual case undergoing
mutation corresponds to a specific entry in either T or U. This entry is
described by its VNTR genotype Vi = (Vi,1, . . . , Vi,L) where L = 15 for the
Bolivian data, and its resistance profile, k = 0, INH, RIF, MDR. The result
of the mutation is a change to the VNTR genotype, which is represented by
a change in the repeat number at a single locus, Vij, by ±1. This may or may
not result in a VNTR genotype that is already present in the population.
If the new VNTR genotype already appears as a row in the matrix V as
an existing type in the data, then there is no change to V. The matrix T or
U on the other hand is changed by subtracting 1 from one entry and adding
one to another entry in the same column (the resistance profile, k, does not
change). In matrix terms, supposing the change is to a treated case, this can
be described by updating T→ T− ei,j + ei,k, where ei,j is the matrix whose
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entries are zero except for a 1 in the (i, j)-th position, and where the VNTR
genotype changes from row j to row k.
If the new VNTR genotype does not already appear in the population,
then the matrix V is expanded to include a new row describing the new
genotype, so that V becomes a (G + 1) × 15 matrix. The update for T
or U is the same as described above, except that now both matrices are
(G+1)×4 dimensional. Subsequent to this update we increment G→ G+1.
If mutation of a VNTR genotype removes the last instance of the original
genotype from U and T the corresponding rows of matrices V, U and T are
deleted, requiring the update G→ G− 1.
3.6 Initial conditions of the model
The model covers the period from when drugs are introduced at time t = 0 to
when sampling occurs. Since the main first-line anti-tuberculosis drugs were
discovered/developed in the 1940s to early 1960s, we assumed treatment
commenced around 1960 and ran the simulation for a period of 50 years.
We assumed that both drugs, isoniazid and rifampicin, were introduced at
the same time and are administered together in combination therapy. The
standard course of treatment includes both drugs along with other first-line
drugs (WHO 2015).
We assume that at the start of the process all cases are sensitive to both
drugs and that the number of cases is at equilibrium in the absence of treat-
ment and resistance. To compute this equilibrium state, we consider the dif-
ferential equation describing the deterministic version of the model ignoring
VNTR genotypes. Namely,
dU
dt
= (β/N)SU − δU
where S = N −U and t indicates time. Setting dU/dt to zero and solving for
the dynamic variables we obtain equilibrium values of
Uˆ = N
(
1− δ
β0
)
and Sˆ =
δN
β
for U > 0.
The basic reproduction number of a pathogen R0 is defined to be the
average number of new infectious cases caused by a single infection in a com-
pletely susceptible population. In our model, before there is any treatment,
assuming all cases are doubly susceptible, a single case on average persists
for 1/δ years and generates Sβ0/N new cases per unit time but since S = N
in a wholly susceptible population then R0 = β0/δ.
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All cases are initially untreated and sensitive. From time t = 0 treat-
ment in the population commences. To reintroduce into the model genetic
variation at the marker loci, the initial distribution of genotype clusters is a
random sample drawn from the infinite alleles model from population genetic
theory (Ewens 1972; Hubbell 2001; Luciani et al. 2008). The infinite alleles
model depends on a single parameter, the diversity parameter, which we set
to 2UˆµL where Uˆ is the number of cases, taken from the equilibrium value
described above, µ is the mutation rate per VNTR locus and L is the num-
ber of VNTR loci used in genotyping isolates. To initialise the multi-locus
VNTR genotypes, each genotype is a sequence of random integers, of length
L, with each VNTR number Vij drawn from a discrete uniform distribution
over {1, . . . , 10}. Although the initial distribution of genotype clusters is set
under the infinite alleles model, the mutation process for VNTRs brings the
distribution in line with the stepwise model over time.
The initial conditions are a function of the parameters which are set
according to the priors specified in Section 4.2.
4 Inference with approximate Bayesian com-
putation
For the model in Section 3, when the data are only observed at a single point
in time, the cost of evaluating the likelihood function is computationally pro-
hibitive. This results from the “incomplete” nature of the observed data (see
Section 2) in the sense that we only have access to a snapshot of the popu-
lation, via the observed sample, at the time the study was conducted, with
no direct measurements of the system as it progressed. Computing the likeli-
hood then requires integrating over all potential trajectories the population
could have gone through before reaching its final, observed state.
As such we adopt approximate Bayesian computation (ABC) methods as
a means of performing Bayesian statistical inference for the unknown model
parameters θ = (β0, µ, ρINH, ρRIF, ρMDR)
>. As observed in other chapters in
this Handbook, the ABC approximation to the true posterior distribution is
given by
piABC(θ|sobs) ∝ pi(θ)
∫
Kh(‖s− sobs‖)p(s|θ)ds,
where pi(θ) is the prior distribution, s = S(X) is a vector of summary statis-
tics with sobs = S(Xobs), p(s|θ) is the computationally intractable likelihood
function for the summary statistics s, and Kh(u) = K(u/h)/h is a standard
smoothing kernel with scale parameter h > 0. In the following analyses we
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used the uniform kernel on [−h, h] for Kh(u). The quality of the ABC ap-
proximation depends on the information loss in the summary statistics s over
the full dataset X, and the size of the kernel scale parameter h with smaller
h producing greater accuracy and increased computational cost. Choice of
both s and h are typically driven by the amount of expert knowledge and
computation available for the analysis.
For the present analysis we implement a version of a simple ABC
importance sampling algorithm, as outlined in the box. Given a suit-
able importance sampling distribution q(θ), the algorithm produces a set
of weighted samples from the ABC approximation to the true posterior
(θ(1), w(1)), . . . , (θ(N˜), w(N˜)) ∼ piABC(θ|sobs). As with standard importance
sampling, suitable choice of q(θ) is important to avoid high variance in
the importance weights, and also to avoid needlessly generating datasets
s = S(X(i)), X(i) ∼ p(X|θ) for which s(i) and sobs will never be close.
ABC Importance Sampling Algorithm
Inputs:
• A target posterior density pi(θ|Xobs) ∝ p(Xobs|θ)pi(θ), consisting of a
prior distribution pi(θ) and a procedure for generating data under the
model p(Xobs|θ).
• A proposal density q(θ), with q(θ) > 0 if pi(θ|Xobs) > 0.
• An integer N˜ > 0.
• An observed vector of summary statistics sobs = S(Xobs).
• A kernel function Kh(u) and scale parameter h > 0.
Sampling:
For i = 1, . . . , N˜ :
1. Generate θ(i) ∼ q(θ) from sampling density q.
2. Generate X(i) ∼ p(X|θ(i)) from the likelihood.
3. Compute the summary statistics s(i) = S(X(i)).
4. Assign θ(i) the weight w(i) ∝ Kh(‖s(i) − sobs‖)pi(θ(i))/q(θ(i)).
Output:
A set of weighted parameter vectors {(θ(i), w(i))}N˜i=1 ∼ piABC(θ|sobs).
To determine a suitable importance sampling distribution q(θ) we adopt
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a two stage procedure, following the approach of Fearnhead and Prangle
(2012). In the first stage we perform a pilot ABC analysis using a sam-
pling distribution that is diffuse enough to easily encompass the ABC pos-
terior approximation obtained for a moderate value of the kernel scale pa-
rameter h. We specified q(θ) ∝ pi(θ)I(θ ∈ A) which is proportional to the
prior, but restricted to the hyper-rectangle A. Here, A is constructed as
the smallest credible hyper-rectangle that we believe contains the ABC pos-
terior approximation. As such, this q(θ) will identify the general region in
which piABC(θ|sobs) is located. Specifically, for θ = (β0, µ, ρINH, ρRIF, ρMDR)>
we adopt q(θ) = p˜i15(β0) × U(0, .005) × U(0, .01) × U(0, .005) × U(0, .001),
where p˜i15(β0) is the prior pi(β0) for β0 specified in Section 4.2, but truncated
to exclude density above the point β0 = 15.
For posterior distributions with strong dependence between parameters,
defining q(θ) over such a hyper-rectangle may be inefficient as it will cover
many regions of effectively zero posterior density. Accordingly we construct
the sampling distribution for the second stage, with the lowest value of h,
as a kernel density estimate of the previous ABC estimate of the posterior
distribution: q(θ) =
∑
iw
(i)L(θ|θ(i)), where L is a suitable kernel density (not
to be confused with the kernel Kh). This approach follows the ideas behind
the sequential Monte Carlo-based ABC samplers of Sisson et al. (2007) and
others. At each stage the kernel scale parameter h is decreased, and deter-
mined as the value which results in ∼ 2,000 posterior samples with non-zero
weights, for the given computational budget.
To ensure greater efficiency at each stage we also performed a non-linear
regression adjustment using a neural network with a single hidden layer (see
Blum and Franc¸ois 2010; Csille´ry et al. 2012; Beaumont et al. 2002), as imple-
mented in the R package abc. The adjustment used logistic transformations
for the response.
For samples drawn from the final importance sampling distribution q(θ),
the data generation procedure took on average ∼ 40 seconds in R. This is
computationally expensive from an ABC context, and could be reduced by
recoding the simulator in a compiled language such as C, or by adapting
the “lazy ABC” ideas of Prangle (2016) to terminate early those simulations
that are likely to be rejected. In this implementation we performed impor-
tance sampling from each distribution q(θ) in parallel on multiple nodes of a
computational cluster.
4.1 Summary statistics
Considering the matrix structure of the observed data Xobs (see Section 2),
we determine the information content in X as if it was the design matrix
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of a regression model and summarise it accordingly. Specifically, we define
the summary statistics s = S(X) to be the upper-triangular elements of the
matrix
(1g|X)>(1g|X),
where the vertical lines denote the addition of an extra column. The added
columns of ones enriches the set of summary statistics by including the row
and column totals of X. Alternatively, these summary statistics can be de-
scribed as:
i) g: the number of distinct genotypes in the sample.
ii) nk: the number of isolates with resistance profile k = 0, INH, RIF and
MDR.
iii) ck,k′ = (Xk)
>Xk′ : the dot product between the resistance profiles of k
and k′ within X.
Note that these summary statistics are over specified in that n0 +nINH +
nRIF + nMDR equals the total number of isolates sampled from the popula-
tion, which is known and equal to the number of isolates in the observed
data sample (100 for the Bolivian data). Accordingly, and without loss of
generality, we remove nMDR as a summary statistic to avoid collinearity. In
combination, this set of 14 summary statistics efficiently encapsulates the
available information about the covariance structure of the original dataset
X, the distribution of the isolates among the different resistance profiles and
the degree of diversity of isolates within the sample.
For the Bolivian dataset, there are g = 68 distinct genotypes, n0 = 78
sensitive isolates, nINH = 8 isolates resistant to isoniazid only, nRIF = 0
isolates resistant to rifampicin only and nMDR = 16 doubly resistant isolates
(see Table 1). The remaining statistics, ck,k′ , are computed as:
0 INH RIF MDR
0 232 15 0 1
INH – 10 0 6
RIF – – 0 0
MDR – – – 18
Finally, in order to reduce the impact of summary statistics operating
on different scales, we compare simulated and observed summary statistics
within the kernel Kh(‖s− sobs‖) via the L 1
2
norm
‖s− sobs‖ = ‖S(X)− S(Xobs)‖ =
dim(s)∑
j=1
[S(X)j − S(Xobs)j]
1
2
2 ,
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where dim(s) = 14 is the number of summary statistics. Alternative ap-
proaches could rescale the statistics via an appropriate covariance matrix (e.g.
Luciani et al. 2009; Erhardt and Sisson 2016) or use other norms, however
the results in the following Section proved to be robust to more structured
comparisons, so we did not pursue this further. In particular the following
results were robust to these choices because of the use of a good (non-linear)
regression adjustment, which greatly improves the ABC posterior approxi-
mation, and which has a larger impact on this approximation than the choice
of metric ‖ · ‖.
4.2 Parameter specifications and prior distributions
Of the 13 model parameters (see Table 3), eight of these are known well
enough for the purposes of our analysis to fix their values. Namely, the pa-
rameters (δ, γ0, γINH, γRIF, γMDR, N, τ, c)
> are set to these fixed values. We
justify our choices for these values below. The remaining five parameters
θ = (β0, µ, ρINH, ρRIF, ρMDR)
> are to be estimated, and require a prior distri-
bution specification.
The rate of death or recovery, δ, is fixed and set to be δ = 0.52 per case
per year following Dye and Espinal (2001) and Cohen and Murray (2004).
Similarly, following Dye and Espinal (2001), untreated individuals are de-
tected and treated at rate τ = 0.5 per case per year. The rates of recovery
due to treatment, γk, for resistance profiles k = 0, INH, RIF and MDR, can
be written in terms of the probability of treatment success
pk =
δr + γk
δd + δr + γk
.
We set the cure rates to be γ0 = 0.5, γINH = γRIF = 0.25, γMDR = 0.05,
which, by using δr = 0.2 (Dye and Espinal 2001; Cohen and Murray 2004),
corresponds to treatment success probabilities of approximately p0 = 0.69,
pINH = pRIF = 0.58 and pMDR = 0.44. These values are within the supported
ranges in the literature, namely, p0 = 0.45 − 0.75, pINH = pRIF = 0.3 − 0.6
and pMDR = 0.05 − 45 (Blower and Chou 2004). We chose higher values
within these ranges since Blower and Chou (2004) explored a wide range of
possibilities in models including epidemiologically pessimistic scenarios.
The fitness cost of drug resistance, c, was fixed and set to be c = 0.1
based on estimates by Luciani et al. (2009). To set the total population
size N we first observe that because the sample of 100 isolates represents
∼ 1.1% of the population, this implies that the infected population is 9091.
We expect that the number of susceptible individuals who are exposed to
disease is somewhat higher than this. Accordingly, we assumed that the total
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size of the population susceptible to tuberculosis is N = 10, 000. Larger total
population sizes can be used, at the price of greater computational overheads
for generating data under the model.
Previous work estimated rates of resistance acquisition by mutation to
be around 0.0025− 0.02 per case per year (Luciani et al. 2009). The rate of
mutation of the VNTR loci in M. tuberculosis was estimated to be around
10−3 per locus per case per year (Reyes and Tanaka 2010; Aandahl et al. 2012;
Ragheb et al. 2013) but lower estimates have also been found (Wirth et al.
2008; Supply et al. 2011). All of these mutation rates are much lower than 1.
We treat these mutation rate parameters as probabilities and conservatively
set the standard uniform distribution as a wide prior on each parameter.
That is, for the acquisition of resistance to isoniazid or rifampicin (or both),
we specify priors for the rates of resistance acquisition as ρINH, ρRIF, ρMDR ∼
U(0, 1). Similarly, for the mutation rate of the VNTR molecular marker, µ,
we use the prior µ ∼ U(0, 1).
The transmission parameter for doubly sensitive strains β0 is given the
shifted gamma prior
β0 − 0.68 ∼ Gamma(shape = 2, rate = 0.73)
where the parameters are chosen such that the resulting prior distribution of
the basic reproduction number R0 closely resembles the distribution obtained
in a numerical analysis of tuberculosis dynamics by Blower et al. (1995).
Note that the prior on β0 is shifted in order ensure the realistic condition
that R0 > 1. A value of R0 lower than unity would lead to extinction of M.
tuberculosis.
We reiterate that we interpret the rate parameters as probabilities per
time step and handle the parameters so that their values remain in (0,1).
This approximation increases in accuracy as the time unit decreases. Here
we divide the natural time unit of one year into new units of 1/12 year per
time step.
5 Competing models of resistance acquisition
We estimate the rates of acquisition of drug resistance to rifampicin and iso-
niazid by fitting the model described in Section 3 to the Bolivian data (Mon-
teserin et al. 2013) with the ABC method described in Section 4. Addi-
tionally, by constraining particular resistance-acquisition parameters ρk to
produce meaningful submodels of the full model, we are able to examine
two specific biological questions. The relationships between the two submod-
els and the full model are illustrated in Figure 3. First, we ask whether it
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is possible for multidrug resistance to evolve directly from doubly sensitive
bacteria or whether this direct conversion does not occur (i.e., ρMDR = 0:
Submodel 1). Second, we ask whether differences between rates of mutation
to rifampicin and isoniazid resistance are apparent at the epidemiological
scale (i.e., ρINH = ρRIF = ρsingle: Submodel 2).
ρINH
ρINH
ρRIF
ρRIF
ρMDR
(a) Full model
ρINH
ρINH
ρRIF
ρRIF
(b) Submodel 1
ρsingle
ρsingle
ρsingle
ρsingle
ρMDR
(c) Submodel 2
Figure 3: Three candidate models of acquisition of multiple drug resistance. (a)
The full model: two different rates of conversion leading to acquisition of resis-
tance and a rate of conversion from resistance profile 0 to resistance profile MDR.
This model is also shown in Figure 2. (b) Submodel 1: no direct conversion from
resistance profile 0 to resistance profile MDR (ρMDR = 0). (c) Submodel 2: same
rate of conversion for the two drugs (ρINH = ρRIF = ρsingle).
Figure 4 illustrates the ABC marginal posterior density estimates of each
parameter under the three different sets of model assumptions. Under the
full model there is a clear visual difference between the rates of mutation of
rifampicin and isoniazid resistance, with the latter occurring at a much higher
rate. In contrast, the rate of simultaneous resistance acquisition appears to
be higher than that for rifampicin alone. When eliminating the possibility
of simultaneous acquisition of multiple drug resistance ρMDR = 0 (Submodel
1), ρINH and ρRIF both increase, relative to the full model, to compensate
for the imposed restriction when fitting to the observed data (Figure 4b).
Similarly, when we fix the identity ρINH = ρRIF = ρsingle (Submodel 2) to
impose a single rate of resistance acquisition, the posterior density of this
parameter moves to intermediate values compared to the two distinct rates
of acquisition estimated under the full model (Figure 4c). The estimated
posterior densities for the transmission (β0) and mutation (µ) parameters
are visually similar across all models. ABC marginal posterior means and
highest posterior density (HPD) credible intervals for all models are reported
in Table 4.
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(c) Submodel 2: ρINH = ρRIF =
ρsingle
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(d) Posterior density of β0
Figure 4: Estimated ABC marginal posterior densities for each estimated param-
eter under (a) the full model, (b) Submodel 1 (ρMDR = 0), and (c) Submodel 2
(ρINH = ρRIF = ρsingle). Panel (d) shows the estimated ABC marginal posterior
density of the transmission rate β0 of the sensitive strain for each model structure.
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ρINH ρRIF ρMDR µ β0
Full model
Posterior mean 1.14× 10−3 1.67× 10−4 2.62× 10−4 1.64× 10−3 2.85
CI lower limit 3.40× 10−4 3.82× 10−6 3.93× 10−6 1.11× 10−3 0.97
CI upper limit 1.94× 10−3 4.28× 10−4 5.81× 10−4 2.40× 10−3 5.33
Submodel l
Posterior mean 1.60× 10−3 6.37× 10−4 – 1.59× 10−3 3.29
CI lower limit 4.55× 10−4 1.27× 10−4 – 1.03× 10−3 1.20
CI upper limit 2.49× 10−3 1.24× 10−3 – 2.19× 10−3 5.78
Submodel 2
Posterior mean 3.46× 10−4 – 1.56× 10−4 1.70× 10−3 2.81
CI lower limit 7.26× 10−5 – 6.62× 10−7 1.10× 10−3 0.86
CI upper limit 6.90× 10−4 – 3.76× 10−4 2.54× 10−3 5.20
Table 4: ABC posterior means with lower and upper limits of the 95% HPD
(highest posterior density) credibile intervals for each parameter of each fitted
model.
5.1 Can resistance to both drugs be acquired simulta-
neously?
To determine whether resistance to both drugs can evolve directly from a dou-
ble sensitive strain within an infection, we compare Submodel 1 (ρMDR = 0)
against the full model. Formal standard Bayesian model comparison typically
occurs through Bayes factors. In the ABC framework this task is complicated
by the need to perform ABC with summary statistics that are informative
for the model indicator parameter, in addition to those informative for the
model specific parameters. Such summary statistics can not only be difficult
to identify, but the resulting composite vector of summary statistics can be
high dimensional, which may then produce more inaccurate inference than if
each model was analysed independently. See e.g. Robert et al. (2011), Marin
et al. (2014) and Marin et al. (2017, this volume) for a discussion of these
issues. A useful alternative is to consider posterior predictive checks or re-
lated goodness-of-fit tests (e.g. Thornton and Andolfatto 2006; Csillery et al.
2010; Aandahl et al. 2012; Prangle et al. 2014).
Figure 5 shows the posterior predictive distribution of the summary statis-
tics (n0, nINH+nRIF, nMDR) described in Section 4.1, for the full model (panel
(a)) and Submodel 1 (panel (b)), where a darker intensity indicates higher
density. This predictive distribution graphically illustrates each model’s abil-
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ity to generate the observed summary statistics (78, 8, 16), indicated by the
asterisks, which represent the number of individuals in the sample sensitive
to both drugs (n0), resistant to a single drug (nINH + nRIF) and resistant to
both drugs (nMDR).
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Figure 5: Posterior predictive distribution of (n0, nINH+nRIF, nMDR) under the full
model (panel (a)) and Submodel 1 (panel (b)). Darker intensity indicates higher
posterior density. The asterisk (*) indicates the observed data (78, 8, 16).
The predictive distributions for each model are diffuse, particularly for
the full model. This variability is expected given that the sample size is small
(100 isolates) and that the evolution of drug resistance from sensitivity is a
relatively rare stochastic event. In the case of Submodel 1 (Figure 5 panel (b))
where we impose the condition ρMDR = 0, the density of samples is shifted
away from the bottom-right corner which represents double resistance. This
pattern is due to the lack of the direct route to multidrug resistance. The
observed data (asterisk) is in a region of low posterior predictive density
under Submodel 1, and so we conclude that this model is not particularly
supported by the data. In contrast, the observed data lie more clearly within
a moderately high density region of the posterior predictive under the full
model (Figure 5 panel (a)). This analysis therefore suggests that of the two
competing hypotheses, it is more likely that resistance to both drugs can be
acquired simultaneously (ρMDR > 0) than otherwise. Note, however, that this
direct route is not the only possible path to double resistance, which can still
occur in stages through single resistance.
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5.2 Is resistance to both drugs acquired at equal rates?
In order to determine whether the rates of acquisition of resistance to the
two drugs are equal (ρINH = ρRIF), we compare Submodel 2 against the full
model. Figure 6 depicts the posterior predictive distribution of (nINH, nRIF)
under each model – the number of cases resistant only to isoniazid (nINH) and
the number of cases resistant only to rifampicin (nRIF) in the sample. The
observed values of these summary statistics are nINH = 8 for isoniazid and
nRIF = 0 for rifampicin, illustrated as the asterisk in Figure 6. As Submodel
2 does not favor any drug over the other, the predictive surface is symmetric
with respect to the line nINH = nRIF. The extra flexibility provided by the full
model shifts the predictive distribution towards the observed data. While the
distribution under the full model comfortably accommodates the empirical
point in a high density region, the predictive distribution under Submodel
2 is much more diffuse. This indicates that while the observed data is not
unsupported under Submodel 2, it is far more likely to be observed under the
full model. As a result, we conclude that the evidence favours the drugs being
acquired at different rates; specifically, isoniazid resistance evolves faster than
rifampicin resistance.
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Figure 6: Posterior predictive distribution of (nINH, nRIF) under the full model
(panel (a)) and Submodel 2 (panel (b)). Darker intensity indicates higher posterior
predictive density. The asterisk (*) indicates the observed data (8, 0).
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5.3 The relative contribution of transmission and
treatment failure to MDR-TB
In addition to estimating the rates of acquisition of drug resistance and as-
sessing whether rates differ, we may also consider where doubly resistant
cases come from. That is, estimation of the relative contribution to mul-
tidrug resistant cases of transmission of existing MDR-TB strains compared
to treatment failure leading to evolution of multidrug resistance. The poste-
rior predicted samples generated under the full model provide a clear por-
trait of the relative contribution of the different paths to achieving double
resistance (see e.g. Luciani et al. 2009 for an additional illustration of this
procedure).
Table 5 shows the means, medians and the 95% HPD credible intervals
for the predicted proportion of cases of double resistance from each potential
source. These proportions are obtained conditionally on there being at least
one case of double resistance in the predictive sample. Simulated samples
of this nature account for 99.67% of all predictive samples. The predictive
distributions of the proportions are highly asymmetric (not shown), making
the median a more reliable point estimate than the mean.
In the overwhelming majority of posterior predictive samples, direct
transmission was the main source of acquisition of double resistance, fol-
lowed by conversion in a single step directly from a sensitive profile (from
profile 0 to MDR) and conversion in two steps via a state of resistance to
a single drug (from profile 0 to INH to MDR, or from 0 to RIF to MDR).
This analysis corroborates the finding from Section 5.1 that ρMDR is most
likely positive, and furthermore that this path is likely to be of even greater
importance than conversion in two steps.
Source Median Mean 95% Credible Interval
Transmission 0.9975 0.9655 (0.7826, 0.9999)
Conversion in one step 0.0023 0.0284 (0.0000, 0.1667)
Conversion in two steps 0.0000 0.0060 (0.0000, 0.0073)
Table 5: Contributions to MDR-TB from alternative sources. This table contains
the posterior medians and means and lower and upper limits of the 95% HPD
credibility intervals for the proportion of double resistance cases originating from
each possible source.
26
6 Conclusions
In this chapter we have estimated epidemiological parameters describing the
acquisition of multi-drug resistance in M. tuberculosis from molecular epi-
demiological data (Monteserin et al. 2013) using approximate Bayesian com-
putation. The underlying model is intended to capture essential processes
that give rise to the data, namely, transmission of the disease, recovery or
death, and within-host evolution giving rise to drug resistance and new geno-
types at the molecular marker loci. From this analysis we may draw three ma-
jor biological conclusions about the manner in which drug resistance arises.
First, there is an asymmetry in the acquisition of resistance to isoni-
azid and rifampicin. Specifically, isoniazid resistance occurs approximately
an order of magnitude more frequently than resistance against rifampicin
(see Table 4). This asymmetry in rates is consistent with in vitro (that is,
through laboratory experiments) microbiological estimates of mutation rates
per cell generation which find around 1 to 2 orders of magnitude difference
between the two rates (David 1970; Ford et al. 2013).
Second, the analysis supports the occurrence of direct conversion from
doubly drug sensitive to doubly resistant (MDR) infections. This may be ini-
tially unintuitive because under mutation alone, if mutation occurs at rate
ρ per gene per unit time, the rate of appearance of double mutants is ρ2,
which would be vanishingly small if ρ is low. However, using a mathematical
model, Colijn et al. (2011) argued that direct conversion can occur surpris-
ingly fast because resistant cells are sometimes present at low frequencies in
a within-host population even before treatment commences. Our analysis of
data at the epidemiological level is consistent with that theoretical result.
This direct conversion to double resistance is epidemiologically important
as it accelerates the accumulation of resistance, in that resistance evolution
does not have to take place sequentially. Once double resistant mutants ap-
pear, transmission of these mutants further increases their prevalence in the
population.
Third, the overwhelming majority of cases of multidrug resistant tuber-
culosis come from transmission of already multidrug resistant strains (see
Table 5), a finding that is consistent with those of Luciani et al. (2009).
This large contribution of transmission occurs despite the 10% transmission
cost of each resistance which results in a ∼ 20% cost for MDR-TB. This
implies that in controlling drug resistance, although there is widespread con-
cern about treatment failure leading to rising resistance, most resistant cases
may be due to transmission. Therefore, although it is important to support
treatment adherence, public health efforts may benefit from focusing more
on preventing disease transmission. That is, control measures that reduce the
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incidence of new cases are likely to help reduce MDR-TB.
By developing epidemiological models with evolutionary processes we
have been able to estimate parameters describing how drug resistance – par-
ticularly multidrug resistance – emerges in M. tuberculosis. Although there is
existing knowledge of rates of mutation to resistant states in vitro, there is a
need to assess the extent to which those rates translate to the epidemiological
level. Large scale molecular epidemiological models, such as those presented
here, are highly complex and multidimensional, and as such, likelihood-based
analyses are not straightforward mathematically or computationally. In such
cases, approximate Bayesian computation methods present a practical and
viable approach to making statistical inferences, particularly as continually
advancing molecular technologies require dynamical models to be extended
and refined.
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